Screener
Kura Oncology KURA Deferred Revenue
Deferred Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | March 31, 2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $7,043 | $5,017 |
| Accrued expenses and other current liabilities | 45,466 | 61,697 |
| Current operating lease liabilities | 1,283 | 1,277 |
| Current portion of contract liabilities | 47,704 | 48,983 |
| Total current liabilities | 101,496 | 116,974 |
| Long-term debt, net | 9,749 | 9,711 |
| Long-term operating lease liabilities | 13,241 | 9,469 |
| Other long-term liabilities | 3,437 | 3,165 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's deferred revenue?
- Kura Oncology (KURA) reported deferred revenue of $47.7M in Q1 2026.
- How has Kura Oncology's deferred revenue changed year-over-year?
- Kura Oncology's deferred revenue increased by 16.8% year-over-year, from $40.85M to $47.7M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Kura Oncology's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude